Evusheld May Not be Effective Against New COVID-19 Subvariant

SARS-CoV-2 Omicron variant XBB.1.5 now accounts for 28 percent of the virus circulating in the U.S. The FDA is closely monitoring this subvariant because it is similar to other subvariants against which Evusheld is not effective. Evusheld is currently the only option for pre-exposure prophylaxis of COVID-19 and is authorized under Emergency Use Authorization (EUA) for use in immunocompromised individuals who may not mount an adequate response to COVID-19 vaccination, and for individuals for whom COVID-19 vaccination is not recommended due to a history of a severe adverse reaction. Read more.